{"protocolSection":{"identificationModule":{"nctId":"NCT05987397","orgStudyIdInfo":{"id":"202306124"},"organization":{"fullName":"Xiangya Hospital of Central South University","class":"OTHER"},"briefTitle":"Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy","officialTitle":"Clinical Multi-center Study of Mitochondrial Brain Protective Agent Idebenone in the Prevention of Post-stroke Epilepsy"},"statusModule":{"statusVerifiedDate":"2023-07","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-07-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-07-19","studyFirstSubmitQcDate":"2023-08-03","studyFirstPostDateStruct":{"date":"2023-08-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-03","lastUpdatePostDateStruct":{"date":"2023-08-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Li Feng, MD, PhD","investigatorTitle":"Associate Professor Vice Director of Neurology Teaching and Research Office","investigatorAffiliation":"Xiangya Hospital of Central South University"},"leadSponsor":{"name":"Xiangya Hospital of Central South University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"According to the random number table, all patients were divided into short-term treatment group, long-term treatment group and non-intervention stroke control group according to the proportion of (1:1:1) epilepsy disease modifier idebenone. Patients in the short-term treatment group will take idebenone for a total course of 14 days (acute period) after stroke, and patients in the long-term treatment group will take idebenone for a total course of 3 months after stroke."},"conditionsModule":{"conditions":["Post Stroke Epilepsy"],"keywords":["post-stroke epilepsy","idebenone"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2700,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A: Idebenone short-term treatment group","type":"EXPERIMENTAL","description":"The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).","interventionNames":["Drug: idebenone 30 mg for 14 days"]},{"label":"Group B: Idebenone long-term treatment group","type":"EXPERIMENTAL","description":"The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.","interventionNames":["Drug: idebenone 30 mg for 3 months"]}],"interventions":[{"type":"DRUG","name":"idebenone 30 mg for 14 days","description":"The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).","armGroupLabels":["Group A: Idebenone short-term treatment group"]},{"type":"DRUG","name":"idebenone 30 mg for 3 months","description":"The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.","armGroupLabels":["Group B: Idebenone long-term treatment group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of patients with epilepsy after stroke","description":"Count the number of people with post-stroke epilepsy","timeFrame":"At the time of enrollment"},{"measure":"The proportion of patients with epilepsy after stroke","description":"Count the number of people with post-stroke epilepsy","timeFrame":"24 weeks after enrollment"},{"measure":"The proportion of patients with epilepsy after stroke","description":"Count the number of people with post-stroke epilepsy","timeFrame":"48 weeks after enrollment"}],"secondaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients","timeFrame":"At the time of enrollment"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients","timeFrame":"24 weeks after enrollment"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients","timeFrame":"48 weeks after enrollment"},{"measure":"Hamilton Anxiety Scale (HAMA)","description":"The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety","timeFrame":"At the time of enrollment"},{"measure":"Hamilton Anxiety Scale (HAMA)","description":"The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety","timeFrame":"24 weeks after enrollment"},{"measure":"Hamilton Anxiety Scale (HAMA)","description":"The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety","timeFrame":"48 weeks after enrollment"},{"measure":"Hamilton Depression Scale (HAMD)","description":"The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression","timeFrame":"At the time of enrollment"},{"measure":"Hamilton Depression Scale (HAMD)","description":"The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression","timeFrame":"24 weeks after enrollment"},{"measure":"Hamilton Depression Scale (HAMD)","description":"The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression","timeFrame":"48 weeks after enrollment"},{"measure":"Pittsburgh sleep quality index (PSQI)","description":"The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality","timeFrame":"At the time of enrollment"},{"measure":"Pittsburgh sleep quality index (PSQI)","description":"The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality","timeFrame":"24 weeks after enrollment"},{"measure":"Pittsburgh sleep quality index (PSQI)","description":"The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality","timeFrame":"48 weeks after enrollment"},{"measure":"Stroke specific quality of life scale (SS-QOL)","description":"The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life","timeFrame":"At the time of enrollment"},{"measure":"Stroke specific quality of life scale (SS-QOL)","description":"The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life","timeFrame":"24 weeks after enrollment"},{"measure":"Stroke specific quality of life scale (SS-QOL)","description":"The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life","timeFrame":"48 weeks after enrollment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed with stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, intracranial venous sinus thrombosis, etc.) after relevant examinations;\n* Able to cooperate with the inspection;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* History of epilepsy before stroke;\n* A history of serious comorbidities that may lead to seizures (including malignant tumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);\n* Secondary stroke caused by head trauma or surgery;\n* Other patients that the researchers think need to be excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Li Feng, PhD","role":"CONTACT","phone":"86-13873123853","email":"fenglihx@163.com"}],"locations":[{"facility":"Xiangya Hospital, Central South University","status":"RECRUITING","city":"Changsha","state":"Hunan","zip":"410008","country":"China","contacts":[{"name":"Li Feng, PhD","role":"CONTACT","phone":"86-13873123853","email":"fenglihx@163.com"}],"geoPoint":{"lat":28.19874,"lon":112.97087}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000004827","term":"Epilepsy"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M7673","name":"Epilepsy","asFound":"Epilepsy","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014451","term":"Ubiquinone"},{"id":"C000036619","term":"Idebenone"}],"ancestors":[{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018977","term":"Micronutrients"}],"browseLeaves":[{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M273880","name":"Idebenone","asFound":"ACE inhibitor","relevance":"HIGH"},{"id":"M271027","name":"Coenzyme Q10","relevance":"LOW"},{"id":"M16891","name":"Ubiquinone","asFound":"ACE inhibitor","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"T383","name":"Coenzyme Q10","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}